Vizag's King George Hospital among 10 centres in country to participate in oral cholera vaccine trials
Tired of too many ads? go ad free now
Of the 1,800 enrolled participants across these 10 sites, 1,794 completed the clinical study, which assessed the safety, immunogenicity, and non-inferiority of Hillchol in comparison to a comparator vaccine in this diverse participant group. Post-vaccination, the percentage of participants in the Hillchol group who exhibited a four-fold increase in anti-Vibrio cholerae antibody titres was 68.25% for Ogawa and 69.52% for Inaba.
For the uninformed, among the various serotypes of the Vibrio cholerae O1 biotype, Ogawa and Inaba are primarily associated with cholera outbreaks, as they exhibit distinct antigenic variations in their lipopolysaccharide structure. Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria.
Approximately, V. cholerae affects 1.3 to 4.0 million people per year, causing between 21,000 and 1.43 lakh deaths worldwide, predominantly in developing nations across Africa, Asia, and the Americas.
Children under five years of age account for about half of all cases and deaths, although individuals of all ages are susceptible.
The World Health Organisation (WHO) recently reported that the dynamics of cholera outbreaks are becoming increasingly complex, with a rise in the number of cases since 2021, highlighting the escalating challenge of controlling V. cholerae infections and transmission.
The global demand for OCVs is close to 100 million doses per year.
Tired of too many ads? go ad free now
Yet, given that only a single manufacturer supplies them, a global shortage persists. According to Bharat Biotech, its facilities in Hyderabad and Bhubaneswar have the capacity to produce up to 200 million doses of Hillchol. The new-generation OCV, featuring a simplified single stable O1 Hikojima strain, aims to enhance production efficiency and affordability.
It induces robust antibodies against both Ogawa and Inaba serotypes, improving accessibility, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.
A total of 1,800 participants were screened based on health status across the 10 trial sites to ensure a diverse demographic analysis. Participants with a history of cholera vaccination or infection, hypersensitivity to past vaccinations, immune disorders, significant acute symptoms, or recent treatment for diarrhoea were excluded. All trial sites were tertiary care centres, including KGH Visakhapatnam, located in urban areas.
Participants were enrolled after obtaining informed consent. The other centres were located in states such as Maharashtra, Telangana, Uttar Pradesh, Goa, and Bihar.
The trial achieved a completion rate of 99% (1,782 participants), with a discontinuation rate of 1% attributed to various reasons. No serious adverse events were reported, with the majority of adverse events being mild. According to the researchers, this highlights the safety of the vaccine as a viable OCV option and the reliability of its manufacturing processes. Its scalability and logistical benefits also highlight its potential to mitigate the OCV shortage.
The study findings have been published in Vaccine, a journal from ScienceDirect.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
10 hours ago
- News18
WHO calls for research scale-up towards ending TB in South-East Asia region
New Delhi, Aug 5 (PTI) The WHO on Tuesday called for urgent scale-up of research, innovation and collaboration to accelerate momentum towards ending tuberculosis in the South-East Asia region, which continues to bear nearly half of the global TB burden, accounting for the highest share of cases and deaths worldwide. Experts, national TB programme managers and researchers along with partners and members of civil society began a three-day virtual workshop organised by the World Health Organization (WHO) for advancing research and innovation to accelerate momentum towards ending TB in the WHO South-East Asia region. 'In our Region alone, nearly 5 million people developed TB and close to 600,000 died from the disease in 2023," said Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia Region. Calling for urgent action, she said that achieving the ambitious targets in the WHO End TB Strategy requires collaboration to accelerate research and innovation. It requires the adoption and use of new tools, technologies and drugs. Ensuring timely and equitable access to these innovations remains critical to achieving impacts at scale, leaving no one behind, Boehme said. While the region recorded a significant increase in TB case notifications in 2023, signalling recovery after COVID-19-related setbacks, progress remains insufficient to meet the End TB Strategy targets aligned with the sustainable development goals that call for a 90 per cent reduction in TB deaths and an 80 per cent reduction in incidence by 2030 compared to 2015 levels. Post-COVID-19 pandemic, TB once again reemerged as the world's leading cause of death from a single infectious agent, the WHO said in a statement. It places a disproportionate burden on the poorest and most vulnerable, further exacerbating inequalities. In the South-East Asia region, 30 per cent to 80 per cent of the TB-affected households experience catastrophic costs, underscoring the need for equitable, people-centred approaches and strengthening social protection for the affected, the statement said. Despite these challenges, the WHO South-East Asia region made notable progress. In 2023, 3.8 million new and relapse TB cases were notified, with an 89 per cent treatment success rate for those who began treatment in 2022. Missed cases dropped to 22 per cent in 2023, down from 44 per cent in 2020, the statement said. Backed by strong political commitment, countries in the region are increasingly leveraging new approaches such as artificial intelligence for case detection, computer-aided diagnostics, digital adherence tools and direct benefit transfers for patients, streamlining the social support process. At the same time, several countries are undertaking important research, including epidemiological research to assess the disease burden, the statement said. Bangladesh recently completed a patient cost survey, while findings from India's RATIONS study on the impact of nutrition on TB outcomes and incidence of the disease have contributed to the global guidance. Social and community-based innovations are also playing a vital role. Nepal's TB-Free Pallika initiative and multisectoral coordination mechanisms in Myanmar are helping reach vulnerable populations with person-centred care. A review by the WHO South-East Asia found that member states published over 3,000 TB-related research articles in the past six years, with 60 per cent being original research. However, uptake of research outcomes remains uneven due to knowledge gaps and limited platforms for knowledge exchange and collaborative use, the statement said. 'Our progress is uneven. Research and innovation capacity is varied across the Region, and the results of these efforts are often siloed and unavailable for collaborative use. The rise in drug-resistant forms of TB remains very concerning," said Dr Boehme. The key areas of focus during the virtual consultation include strengthening of South-South collaboration, vaccine preparedness, digital tools for patient care and adherence and efforts to overcome vaccine hesitancy. Participants will also discuss aligning regulatory processes, promoting data sharing and improving platforms for knowledge exchange. A significant emphasis is being placed on identifying operational implementation research priorities, especially in relation to social determinants such as undernutrition and climate change, which influence TB incidence and outcomes. top videos View all 'Several ongoing innovations are attempting to reach out to marginalized and vulnerable groups through active case finding and providing affected families socio-economic support to mitigate catastrophic costs", said Dr Boehme. Highlighting the importance of equity, she added, 'It is incumbent to ensure equitable access to the benefits of research and innovation, including vaccines, medicines and diagnostics." PTI PLB KSS KSS (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 05, 2025, 19:30 IST News agency-feeds WHO calls for research scale-up towards ending TB in South-East Asia region Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hindustan Times
10 hours ago
- Hindustan Times
Early immunisation critical in preventing RSV in infants
Respiratory illnesses in newborns are a major cause of concern, especially when they involve difficulty in breathing. Among the leading causes is Respiratory Syncytial Virus (RSV), a common and highly severe virus that affects the lungs and airways of infants and children under five. This virus often mimics symptoms of a common cold, such as a runny nose or low-grade fever. This similarity can create confusion for parents and health care providers alike, leading to delays in detection and intervention, which allows the illness to rapidly escalate. Vaccination (Getty Images/iStockphoto) For newborns and infants, whose immune systems are still developing, and airways are small, RSV can quickly become serious. Their tiny airways can get easily blocked by swelling and mucus, leading to lung infections like bronchiolitis or pneumonia. Each year, RSV leads to over 3.6 million hospitalisations and about 100 000 deaths in children under five years of age. As per WHO, most paediatric RSV deaths (97%) occur in low- and middle-income countries where there is limited access to supportive medical care. Even healthy, full-term babies can face complications, and in some cases, require intensive medical care. In India, RSV cases spike during the monsoon and early winter, but the virus can circulate throughout the year. This makes timely protection critical. Medical advancements now offer a way to shield infants through immunisation strategies. While the RSVpreF maternal vaccine is not yet available in India, two monoclonal antibodies have emerged as key preventive options in India. Palivizumab, is administered monthly to high-risk infants such as those born prematurely or with underlying heart or lung conditions. Nirsevimab, on the other hand, is a long-acting monoclonal antibody offering protection with a single-dose. It is designed for all infants regardless of risk category and can be administered soon after birth, before hospital discharge, or during early routine check-ups. Early immunization plays a vital role in protecting infants not just from immediate illness, but also from long-term respiratory complications. Severe RSV infections in the first year of life have been linked to increased risk of recurrent wheezing, asthma, ear infections, and reduced lung function well into adolescence. Infants are especially vulnerable because their immune systems are still developing, and their smaller airways are more easily blocked by inflammation caused by the virus. By providing protection before exposure, through timely use of preventive monoclonal antibodies, we are better equipped to avoid serious outcomes for babies. Parents must understand the importance of stopping the virus before it can take hold, reducing the likelihood of hospitalisation and long-term health issues. For parents and health care providers alike, early immunisation isn't just a seasonal precaution, it's a critical investment in the child's long-term respiratory health and overall well-being. This article is authored by Dr Faisal B Nahdi, paediatrician, Rainbow Children's Hospital, Hyderabad.
Hindustan Times
11 hours ago
- Hindustan Times
What are chikungunya symptoms? CDC issues travel warning for China amid outbreak
Americans travelling to China have been advised to practice utmost caution in the wake of the chikungunya virus outbreak in the country. A Level 2 travel alert was issued by the US Centers for Disease Control and Prevention (CDC) in this regard last week. CDC issued warning for Americans traveling to China after the Chikungunya outbreak.(Unsplash) This comes as more than 7,000 cases of the mosquito-borne virus were reported in the Guangdong province of China, forcing the authorities to put in measures similar to the ones taken during the COVID-19 pandemic period, as per BBC. Among the worst-affected regions in the country is the city of Foshan, where chikungunya patients have been ordered to stay in the hospital until they test negative. They will be discharged at the end of a week-long stay, and their beds are being protected using mosquito nets. Chikungunya: What to know? The viral disease is transmitted mainly through the Aedes mosquitoes. It is caused by the chikungunya virus (CHIKV), which is an RNA virus in the alphavirus genus of the Togaviridae family, as per the World Health Organization (WHO). CHIKV was identified for the first time in the United Republic of Tanzania in 1952, while major outbreaks have been reported in America, Asia, and Africa. A study that came out in Nature in June this year, estimated that around 35.3 million people get infected by Chikungunya on an annual basis across 180 countries and regions. It leads to nearly 3,700 deaths, which is 0.01% of the total cases, as per TIME magazine. The latest outbreak in China has been attributed to imported cases. Liu Qiyong, China CDC's chief expert in vector-borne disease control, told CGTN, 'With the virus spreading globally, imported cases have inevitably reached China.' Chikungunya symptoms The WHO states that chikungunya symptoms are quite similar to dengue and Zika, thus making it difficult to diagnose the disease and accurately determine the total number of infected persons. Also read: Chikungunya outbreak: China on high alert as Guangdong battles over 7,000 cases amid COVID like strict measures Some of the most common symptoms of Chikungunya include high fever, joint pain, headache, muscle pain, as well as joint swelling and rashes. The symptoms usually appear around 4-8 days after the patient is bitten by the infected mosquito. At first, the person gets to witness an 'abrupt onset of fever, frequently accompanied by severe joint pain,' as per the WHO. Notably, the joint pain is often debilitating and can last anywhere from a few days to weeks, months, and even years in some cases. While most of the patients completely recover from the infection, there are cases of eye, heart, and neurological complications that have come up due to the CHIKV infection. FAQs: 1. Why CDC has issued a warning for China? CDC's Level 2 alert, which is designated as 'Practice Enhanced Precautions', came out after China marked over 7,000 cases of chikungunya infections. 2. How are chikungunya patients treated? No specific antiviral treatment is available for the chikungunya virus infections. Usually, doctors give antipyretic and analgesic medications, like paracetamol, for fever and pain, as per the WHO. Also, there are two chikungunya vaccines that have received regulatory approvals, but these are not widely available. 3. Is chikungunya fatal? Severe symptoms and deaths from the viral disease are rare, occurring mostly among young children or elderly people who have co-existing health problems.
